MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
PARP inhibition in cancer therapy
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,206 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,206 works in the cohort · of 4,299,418page 5 of 25

Labels cover 6 of 1,206 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,206 of 1,206 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
When PARPs Meet Antiviral Innate Immunity
Huifang Zhu, Chunfu Zheng
2021· review· en· Trends in Microbiology· Medicine
machine prediction:candidate · noneconsensus · none
59
citations
venueno affunlabeled
Poly(ADP-ribosylation) and genomic stability
Shiao Li Oei, Claudia Keil, Mathias Ziegler
2005· review· en· Biochemistry and Cell Biology· Medicine
machine prediction:candidate · noneconsensus · none
56
citations
affunlabeled
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
Philipp Harter, Fabian Trillsch, Aikou Okamoto, Alexander Reuß, Jae‐Weon Kim, María Jesús Rubio-Pérez +14 more
2023· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
54
citations
affno abstractunlabeled
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers
Kim A. Reiss, Joseph M. Herman, Deborah K. Armstrong, Marianna Zahurak, Anthony Fyles, Anthony Brade +13 more
2017· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
53
citations
fundno affunlabeled
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza +24 more
2020· article· en· Obstetrical & Gynecological Survey· Medicine
machine prediction:candidate · noneconsensus · none
48
citations

How this was built: Screen · Findings · About